The global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market shares of main players, shipments in revenue ($ Million), sales quantity (K L), and ASP (US$/L), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Amgen, Arven Pharmaceuticals, Biocon, Cadila Pharmaceuticals, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Intas Pharmaceuticals, Kyowa Kirin, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Vials
Prefilled
Market segment by Application
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
Major players covered
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy's Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), with price, sales quantity, revenue, and global market share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) from 2020 to 2025.
Chapter 3, the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF).
Chapter 14 and 15, to describe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Vials
1.3.3 Prefilled
1.4 Market Analysis by Application
1.4.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Myelosuppressive Chemotherapy
1.4.3 Leukemia Chemotherapy
1.4.4 Others
1.5 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size & Forecast
1.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (2020-2031)
1.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.1.4 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Abbott Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.2.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Amgen Recent Developments/Updates
2.3 Arven Pharmaceuticals
2.3.1 Arven Pharmaceuticals Details
2.3.2 Arven Pharmaceuticals Major Business
2.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.3.4 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Arven Pharmaceuticals Recent Developments/Updates
2.4 Biocon
2.4.1 Biocon Details
2.4.2 Biocon Major Business
2.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.4.4 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Biocon Recent Developments/Updates
2.5 Cadila Pharmaceuticals
2.5.1 Cadila Pharmaceuticals Details
2.5.2 Cadila Pharmaceuticals Major Business
2.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.5.4 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Cadila Pharmaceuticals Recent Developments/Updates
2.6 Dr.Reddy's Laboratories
2.6.1 Dr.Reddy's Laboratories Details
2.6.2 Dr.Reddy's Laboratories Major Business
2.6.3 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.6.4 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Dr.Reddy's Laboratories Recent Developments/Updates
2.7 Emcure Pharmaceuticals
2.7.1 Emcure Pharmaceuticals Details
2.7.2 Emcure Pharmaceuticals Major Business
2.7.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.7.4 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Emcure Pharmaceuticals Recent Developments/Updates
2.8 Intas Pharmaceuticals
2.8.1 Intas Pharmaceuticals Details
2.8.2 Intas Pharmaceuticals Major Business
2.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.8.4 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Intas Pharmaceuticals Recent Developments/Updates
2.9 Kyowa Kirin
2.9.1 Kyowa Kirin Details
2.9.2 Kyowa Kirin Major Business
2.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.9.4 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Kyowa Kirin Recent Developments/Updates
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.10.4 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Novartis Recent Developments/Updates
2.11 Pfizer
2.11.1 Pfizer Details
2.11.2 Pfizer Major Business
2.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.11.4 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Pfizer Recent Developments/Updates
2.12 Reliance Life Sciences
2.12.1 Reliance Life Sciences Details
2.12.2 Reliance Life Sciences Major Business
2.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.12.4 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Reliance Life Sciences Recent Developments/Updates
2.13 Harbin Pharmaceutical
2.13.1 Harbin Pharmaceutical Details
2.13.2 Harbin Pharmaceutical Major Business
2.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.13.4 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Harbin Pharmaceutical Recent Developments/Updates
2.14 North China Pharmaceutical
2.14.1 North China Pharmaceutical Details
2.14.2 North China Pharmaceutical Major Business
2.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.14.4 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 North China Pharmaceutical Recent Developments/Updates
2.15 Jiuyuan Gene
2.15.1 Jiuyuan Gene Details
2.15.2 Jiuyuan Gene Major Business
2.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.15.4 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Jiuyuan Gene Recent Developments/Updates
2.16 Kexing Biopharm
2.16.1 Kexing Biopharm Details
2.16.2 Kexing Biopharm Major Business
2.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.16.4 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Kexing Biopharm Recent Developments/Updates
2.17 Qilu Pharmaceutical
2.17.1 Qilu Pharmaceutical Details
2.17.2 Qilu Pharmaceutical Major Business
2.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.17.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Qilu Pharmaceutical Recent Developments/Updates
2.18 Quangang Pharmaceutical
2.18.1 Quangang Pharmaceutical Details
2.18.2 Quangang Pharmaceutical Major Business
2.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.18.4 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Quangang Pharmaceutical Recent Developments/Updates
2.19 Sunway Biotech
2.19.1 Sunway Biotech Details
2.19.2 Sunway Biotech Major Business
2.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.19.4 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Sunway Biotech Recent Developments/Updates
2.20 SL Pharmaceutical
2.20.1 SL Pharmaceutical Details
2.20.2 SL Pharmaceutical Major Business
2.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.20.4 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 SL Pharmaceutical Recent Developments/Updates
2.21 Four Rings Bio-Pharmaceutical
2.21.1 Four Rings Bio-Pharmaceutical Details
2.21.2 Four Rings Bio-Pharmaceutical Major Business
2.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.21.4 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.21.5 Four Rings Bio-Pharmaceutical Recent Developments/Updates
2.22 Amoytop
2.22.1 Amoytop Details
2.22.2 Amoytop Major Business
2.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.22.4 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.22.5 Amoytop Recent Developments/Updates
2.23 Wuzhong Pharmaceutical
2.23.1 Wuzhong Pharmaceutical Details
2.23.2 Wuzhong Pharmaceutical Major Business
2.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.23.4 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.23.5 Wuzhong Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Manufacturer
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Manufacturer (2020-2025)
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Manufacturer (2020-2025)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer Market Share in 2024
3.4.3 Top 6 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer Market Share in 2024
3.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Overall Company Footprint Analysis
3.5.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Region Footprint
3.5.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Type Footprint
3.5.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2020-2031)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2020-2031)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Region (2020-2031)
4.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020-2031)
4.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020-2031)
4.4 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020-2031)
4.5 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020-2031)
4.6 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2020-2031)
5 Market Segment by Type
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type (2020-2031)
5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
6.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application (2020-2031)
6.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Application (2020-2031)
7 North America
7.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
7.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
7.3 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
7.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2020-2031)
7.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe
8.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
8.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
8.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
8.3.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2020-2031)
8.3.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region
9.3.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America
10.1 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
10.2 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
10.3 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
10.3.1 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2020-2031)
10.3.2 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
11.3.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics
12.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
12.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints
12.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
13.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Distributors
14.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy's Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical
听
听
*If Applicable.
